Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brodclav is a combination antibiotic containing amoxicillin, a semisynthetic penicillin-class beta-lactam antibiotic, and clavulanic acid (as potassium clavulanate), a beta-lactamase inhibitor. Amoxicillin works by binding to and inactivating penicillin-binding proteins (PBPs) involved in bacterial cell wall synthesis, leading to cell lysis and death. Clavulanic acid acts as a suicide inhibitor of bacterial beta-lactamases, preventing the enzymatic degradation of amoxicillin and restoring its activity against beta-lactamase-producing resistant strains. Brodclav is used to treat a wide range of bacterial infections, including respiratory tract, urinary tract, skin, and soft tissue infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Brodclav.